Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP Pres MedSurg | February 28, 2022 | March 02, 2022 |
| DIVERSIFIED HEALTHCARE TRUSTNASDAQ:DHC · Entity 4565 | Director | June 05, 2023 | June 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 28, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-02-28 · Exercise / conversion · Acquired 2,444 · Balance 2,444 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 2 · 2022-02-28 · Tax withholding · Disposed 718 · Balance 1,726 Row 3 · 2022-03-01 · Sale · Disposed 1,726 · Balance 0 F2: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-02-28 | Direct | 0 |
Reported balance
After 2022-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-28 · Exercise / conversion · Disposed 2,444 · Balance 0 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
F3: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
DIVERSIFIED HEALTHCARE TRUST
Report date June 05, 2023 · Filed June 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 40,000 |
Reported balance
After 2023-06-05 transaction · row 1
1 source rowRow 1 · 2023-06-05 · Grant · Acquired 20,000 · Balance 40,000 F1: Transaction reported is grant of shares pursuant to the Issuer's equity compensation plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction reported is grant of shares pursuant to the Issuer's equity compensation plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2021 Filed Feb 19, 2021 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003181 · doc4.xml · derivative · entry 5 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,005 Underlying: Common Stock · 2,668 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,184 | $37.52 | $44,423.68 |
DisclosureSEC source: 0001225208-21-003181 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,144 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003181 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 42,881 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003181 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,881 Underlying: Common Stock · 42,881 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 13,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003181 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,540 | $38.28 | $58,951.20 |
DisclosureSEC source: 0001225208-21-002709 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,660 F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002709 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,538 Underlying: Common Stock · 2,768 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,228 | $38.39 | $47,142.92 |
DisclosureSEC source: 0001225208-21-002709 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002709 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 22:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 3,193 | $38.85 | $124,048.05 |
DisclosureSEC source: 0001225208-21-002244 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,660 Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 22:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 10,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002244 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,853 F1 · shares: On February 15, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2020 and subject to the completion of the concurrent three-year individual service period. On February 9, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 11,317 | $38.00 | $430,046.00 |
DisclosureSEC source: 0001225208-21-001881 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,057 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Mr. Pierce's holdings include 1,395 shares of common stock, which, due to an administrative error, had not been previously reported. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 16,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-000228 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,318 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. F1 · derivative.exercise_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. F1 · derivative.expiration_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 5,001 | $35.95 | $179,785.95 |
DisclosureSEC source: 0001225208-21-000228 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,979 Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 16,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-000228 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,028 | $39.00 | $79,092.00 |
DisclosureSEC source: 0001225208-20-013294 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,282 | $38.56 | $87,993.92 |
DisclosureSEC source: 0001225208-20-012181 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,690 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 20:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,044 | $40.70 | $83,190.80 |
DisclosureSEC source: 0001225208-20-011201 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,972 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 20:05 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,385 | $38.69 | $92,275.65 |
DisclosureSEC source: 0001225208-20-010202 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,016 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 20:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,170 | $38.00 | $82,460.00 |
DisclosureSEC source: 0001225208-20-009906 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,401 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,624 | $38.00 | $61,712.00 |
DisclosureSEC source: 0001225208-20-008638 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,571 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-008565 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,973 Underlying: Common Stock · 2,972 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017. the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017. the first anniversary of the date of grant. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,969 | $38.00 | $74,822.00 |
DisclosureSEC source: 0001225208-20-008565 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,195 F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,348 | $37.50 | $50,550.00 |
DisclosureSEC source: 0001225208-20-008565 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,164 Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-008565 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,057 | $38.00 | $78,166.00 |
DisclosureSEC source: 0001225208-20-007407 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,540 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 20:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 14,793 | $38.00 | $562,134.00 |
DisclosureSEC source: 0001225208-20-006612 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,597 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,485 | $38.00 | $132,430.00 |
DisclosureSEC source: 0001225208-20-004164 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,390 F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004164 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,888 Underlying: Common Stock · 2,444 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,109 | $37.39 | $41,465.51 |
DisclosureSEC source: 0001225208-20-004164 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,875 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004164 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 4,122 | $41.15 | $169,620.30 |
DisclosureSEC source: 0001225208-20-003570 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,540 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 8,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003570 · doc4.xml · derivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,982 Underlying: Common Stock · 8,982 shares Expires 2021-12-31 F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F3 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F3 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F3 · balance_after: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003297 · doc4.xml · derivative · entry 9 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,453 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,114 | $42.62 | $47,478.68 |
DisclosureSEC source: 0001225208-20-003297 · doc4.xml · nonDerivative · entry 6 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,662 Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003297 · doc4.xml · nonDerivative · entry 5 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003297 · doc4.xml · derivative · entry 8 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,607 Underlying: Common Stock · 2,607 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,184 | $42.62 | $50,462.08 |
DisclosureSEC source: 0001225208-20-003297 · doc4.xml · nonDerivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,323 Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003297 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003297 · doc4.xml · derivative · entry 7 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,478 Underlying: Common Stock · 2,492 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,132 | $42.62 | $48,245.84 |
DisclosureSEC source: 0001225208-20-003297 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,900 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003297 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 19, 2020 Filed Feb 19, 2020 22:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,511 | $42.31 | $63,930.41 |
DisclosureSEC source: 0001225208-20-002842 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,540 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 39,823 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002842 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,823 Underlying: Common Stock · 39,823 shares Expires 2030-02-18 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 10,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002842 · doc4.xml · derivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,673 Underlying: Common Stock · 10,673 shares Expires 2024-02-18 F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002615 · doc4.xml · derivative · entry 5 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,306 Underlying: Common Stock · 2,768 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,257 | $42.31 | $53,183.67 |
DisclosureSEC source: 0001225208-20-002615 · doc4.xml · nonDerivative · entry 4 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,051 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002615 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 7,520 | $42.31 | $318,171.20 |
DisclosureSEC source: 0001225208-20-002615 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,540 Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 20,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002615 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,060 F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.